BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BBIO) Stock Overview
Explore BridgeBio Pharma, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
13.1B
P/E Ratio
-16.31
EPS (TTM)
$-4.21
ROE
0.47%
BBIO Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of BridgeBio Pharma, Inc. (BBIO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 38.47, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $71.84.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -16.31 and a market capitalization of 13.1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.